Test Menu

• Protein detection in tissue specimens, PBMCs, CTCs, rare cell subsets, BMA, FNAs
• Data from high content quantitative image analysis reported as mean fluorescence intensity (MFI) and/or percentage positive on a cell population or per cell basis.
• IHC reporting available as H-Score.

Immunofluorescent / Immunohistochemistry Targets

• Additional markers are available upon request

• Customizable multiplex panels for monitoring various immuno-oncology targets
• Vectra Polaris system enables:
  • Automated tissue classification
  • Nearest neighbor, proximity, infiltration analysis
  • Multiplexed single-cell based analysis in nuclear, cytoplasmic, and membrane compartments
  • Whole slide (up to 4 markers) and multi-spectral (up to 6 markers) imaging

• Phenotypes detected in CTCs enriched from whole blood using the ApoStream platform, a microfluidic, antigen-independent rare cell enrichment device that provides high purity and high recovery of CTCs and other rare cells.
• Data from high content quantitative image analysis reported as total counts on a per mL basis.

• Proprietary panels consisting of multiple phenotypes based on internal data. Additional markers and custom immunofluorescence panels are available upon request. All disease indications are Stage IV unless otherwise noted.

• Cellular subset and biomarker analysis via flow cytometry in whole blood, rare cell subsets, bone marrow aspirates (BMA).
• Biomarker data reported as mean fluorescence intensity (MFI) and/or percentage positive cells; cellular subset data reported as total counts and/or percentage positive cells.

Quantitative Immunofluorescent Phenotype Panels*

• Additional biomarkers and custom flow cytometry panels are available upon request.

• Detection of DNA abnormalities by FISH in tissue specimens, whole blood, rare cell subsets, BMA.
• Data reported as deletion, amplification, or translocations.

Cytogenetic Targets

• Additional custom FISH probes are available upon request.

• Genomic analysis: gene expression and mutation detection (RT-PCR, targeted sequencing and NGS) in tissue specimens, whole blood, CTCs and other rare cell subsets.

Gene Expression Targets

Gene Mutation Targets

Mutations Conferring Resistance to ALK TKI Therapy

• Additional molecular markers and commercially available custom designed NGS panels are available upon request
• ApoCell, Inc. Expands into Europe